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FIGURE S1. ImmunoEM localization of SERA6 to the PV and PVM. Lower magnification 
(x6000) image of the schizont section view shown in the micrograph in Figure 2D of the main 
paper. Note association of gold particles with the PMV (small black arrows) as well as the 
space between merozoites, whilst in contrast the erythrocyte membrane (large black 
arrowheads) is virtually free of label. 
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FIGURE S2. Recombinant expression and purification of PbSERA3. A recombinant form of 
full-length PbSERA3 (rPbSERA3), as well as a mutant in which the putative catalytic Cys641 
residue is replaced by an Ala residue (rPbSERA3C641A) were expressed as secreted 
proteins in baculovirus-infected High FiveTM cells in the presence of 0.5 µg/ml tunicamycin to 
prevent N-glycosylation of the recombinant protein. Culture supernatant (1200 ml) was 
clarified, adjusted to 50 mM Tris-HCl pH 8.2, applied to a HiPrep Q XL 16/10 ion exchange 
column (GE Healthcare, UK) and eluted with a 200 ml gradient of 0-400 mM NaCl in the 
same buffer, collecting 5 ml fractions. Peak fractions were pooled, concentrated, and applied 
to a Superdex 200 HR 10/30 column (GE Healthcare, UK), equilibrated in 25 mM HEPES pH 
7.4, 150 mM NaCl, 12 mM CaCl2, collecting elution fractions of 0.4 ml. Shown are Western 
blot analyses of the indicated elution fractions, probed in all cases with an antibody reactive 
with the central papain-like domain of PbSERA3 (anti-PbS3C1). It can be seen that the 
elution profiles and yields of the two proteins were very similar.  
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FIGURE S3. PfSUB1 correctly cleaves synthetic peptides based on the two predicted 
PbSUB1 cleavage sites in PbSERA3. A. Alignment of the predicted P. falciparum FCBR 
SERA6 sequence (GenBank M55428) with the PbSERA3 sequence (PlasmodDB ID 
PBANKA_030490). Sequences were pairwise aligned using a fast/approximate CLUSTALW 
output tool from the Kyoto University Bioinformatics Center. The alignment was then 
analysed and modified using Jalview 2.7 (1,2) . Positions of identity are shaded in light blue. 
Gaps inserted to improve the alignment are shown as hyphens. The eight residues (P4-P4') 
flanking PfSUB1 cleavage sites in SERA6 (identified in this study) are shown in red, as are 
predicted site 1 and 2 cleavage sites in PbSERA3. The papain-like domain of both 
sequences (Ser606-Lys880 in SERA6) is indicated in dark blue, with predicted catalytic triad 
Cys, His and Asn residues in green. B. Progress curve showing cleavage of fluorogenic 
peptide substrate PbSERA3st1F-6R (0.1 µM) by recombinant PfSUB1 (1.7 U/ml), as 
detected by a time-dependent increase in fluorescence. No cleavage occurred in the 
absence of PfSUB1 or with the additional presence of recombinant PD (85 nM). C. RP-
HPLC fractionation of partially digested PbSERA3st1F-6R. Only two major new fluorescent 
peaks were produced. Their identities, as determined by electrospray mass spectrometry, 
are indicated. Cysteine side chains modified by 6-iodoacetamido tetramethylrhodamine (3) 
are shown (-R). D. RP-HPLC elution profiles of undigested and partially-digested peptide 
PbSERA3st2 (Ac-DVSGQSENHQ). Identities of major peaks determined by mass 
spectrometry (see Supplemental Table S2) are indicated. Note that the highly polar C-
predicted terminal cleavage product (NH2-SENHQ-OH) was not observed, probably due to it 
not being retained by the column as found previously for other digestion products of PfSUB1 
peptide substrates (4-6). 
 
 
 
 
 
5 
 
 
 
 
 
6 
 
 
Table S1. Oligonucleotide primers used in this study 
SERA6_C/A_fwd Forward amplification to 
mutate C644A in sera6synth 
5′- GCAGGGAAACTGTGGTTTGGCTTGGATCTTCGCTTCCAAG -3′ 
 
SERA6_C/A_rev Reverse amplification to 
mutate C644A in sera6synth 
5′- CTTGGAAGCGAAGATCCAAGCCAAACCACAGTTTCCCTGC -3′ 
SERA6st1_mut_fwd Forward amplification to 
mutate SERA6st1 from AQ 
to LL in sera6synth 
5′- GAAGAAAAAGATGAACGAGATCAAGGTTAAGTTATT 
GGATGACTTCAACCCAAACGAGTACAAGTTG -3′ 
 
SERA6st1_mut_rev Reverse amplification to 
mutate SERA6st1 in 
sera6synth 
5′- CTTCTTTTTCTACTTGCTCTAGTTCCAATTCAATAA 
CCTACTGAAGTTGGGTTTGCTCATGTTCAAC-3′ 
SERA6st2_mut_fwd Forward amplification to 
mutate SERA6st2 from 
GQ to LL in sera6synth 
5′- GAACGATTACGACAACGCTTTCGTTCACTTATT 
ATCTGATGAATCCGACGAGACTAACAAA -3′ 
SERA6st2_mut_rev Reverse amplification to 
mutate SERA6st2 in 
sera6synth 
5′- CTTGCTAATGCTGTTGCGAAAGCAAGTGAATAA 
TAGACTACTTAGGCTGCTCTGATTGTTT -3′ 
PbSERA3_C/A_fwd Forward amplification to 
Mutate C641A in 
pbsera3synth 
5′- GGCAACTGCTCCCTGGCCTGGCTGTTCGCTTC -3′ 
PbSERA3_C/A_rev Reverse amplification to 
mutate C641A  in 
pbsera3synth 
5′- GAAGCGAACAGCCAGGCCAGGGAGCAGTTGCC -3′ 
SERA6prom_fwd Forward amplification of 
SERA6 promoter for pHH-
SERA6synth 
5′- GAGATCTGTATCCTTTAATTTTTAAATAGGGCATAAC -3′ 
SERA6prom_rev Forward amplification of 
SERA6 promoter for pHH-
SERA6synth 
5′- GATATCACATAATAATGGACATAACGATAATCTCGAGC -3′ 
SERA6synth_fwd Forward amplification of 
sera6synth for pHH-
SERA6chim 
5′- GCTCGAGGTTAACAAGAACGGTGTTATCTCC -3′ 
 
SERA6synth_rev Reverse amplification of 
sera6synth for pHH-
SERA6chim 
5′- GGTGAAGATTGTAACTTCTGTTATGTTCTCGAGC -3′ 
SERA6gen_homolo
gy_fwd 
Forward amplification of 
genomic SERA6 (region of 
homology) for pHH-
SERA6chim 
5′- CAGTATACATGATATGTCCTATTTTTTAGCTTTTTTAGCTTT -3′ 
 
 
SERA6gen_homolg
y_rev 
Reverse amplification of 
genomic SERA6 (region of 
homology) for pHH-
SERA6chim 
5′- CAAGGATTGATGTTGAGCACAAGGGTGAG -3′ 
a Forward primer  for 
diagnostic PCR, designed 
to hybridize to the 5′ UTR 
of  the SERA6  gene 
5′- AAAAGTAAAAGACCAAATGATA -3′  
b Reverse primer for 
diagnostic PCR, designed 
to hybridize to the 
5′- AAGTAGGAGTCGGACTTAGAA -3′ 
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sera6synth sequence 
c Reverse primer for 
diagnostic PCR, designed 
to hybridize to the 
endogenous SERA6 
coding sequence 
5′- GATTCACTAGGTAATGTTAGACCTC -3′ 
SERA6int_probe_fw
d 
Forward amplification of 
genomic SERA6 for 
Southern blot probe 
5′- CTGTGATATCACATAATAATGGAC -3′ 
SERA6int_probe_re
v 
Reverse amplification of 
genomic SERA6 for 
Southern blot probe 
5′- CAGATGATGATTCAGTTGGAAG -3′ 
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Table S2. Correct cleavage by rPfSUB1 of peptide substrates based on predicted PbSUB1 
processing sites within PbSERA3. 
Peptide name 
 
Peptide sequencea Digestion product  
identifiedb 
Predicted m/zc Measured m/zc 
     
PbSERA3st2 Ac-DVSGQ↓SENHQ Ac-DVSGQ 547.2 547.2 
 
PbSERA3st1F-6R Ac-CVTAQ↓SDEDCd Ac-CVTAQd 1004.5 1004.6 
 
  NH2-SDEDCd 1009.4 1009.5 
 
     
     
     
 
a See Fig. S3 and main paper for the details of predicted PbSERA3 processing sites and 
relevant references. Expected scissile bond is indicated by a downward-pointing arrow. 
b Digestion products were fractionated by RP-HPLC (Fig. S3) and identified by electrospray 
mass spectrometry.  
C Monoisotopic m/z values. 
d PbSERA3st1F-6R is the peptide Ac-CVTAQSDEDC labelled on both cysteine side chains 
with 6-iodoacetamido tetramethylrhodamine, as described previously (3) (see also Fig. S3). 
Cysteine side chains modified by 6-iodoacetamido tetramethylrhodamine are shown (-R). 
The modification results in an increase in mass of each Cys residue of 441.2 Da (3). 
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